|
Background publications
|
Favaloro, Browning, Nandurkar: "The hepatobiliary disease marker serum alanine aminopeptidase predominantly comprises an isoform of the haematological myeloid differentiation antigen and leukaemia marker CD-13/gp150." in: Clinica chimica acta, international journal of clinical chemistry, Vol. 220, Issue 1, pp. 81-90, 1994 (PubMed).
Favaloro, Browning, Facey: "CD13 (GP150; aminopeptidase-N): predominant functional activity in blood is localized to plasma and is not cell-surface associated." in: Experimental hematology, Vol. 21, Issue 13, pp. 1695-701, 1993 (PubMed).
Favaloro: "CD-13 ('gp150', aminopeptidase-N): co-expression on endothelial and haemopoietic cells with conservation of functional activity." in: Immunology and cell biology, Vol. 69 ( Pt 4), pp. 253-60, 1992 (PubMed).
Favaloro, Bradstock, Kabral, Grimsley, Zowtyj, Zola et al.: "Further characterization of human myeloid antigens (gp160,95; gp150; gp67): investigation of epitopic heterogeneity and non-haemopoietic distribution using panels of monoclonal antibodies belonging ..." in: British journal of haematology, Vol. 69, Issue 2, pp. 163-71, 1988 (PubMed).
Bradstock, Favaloro, Kabral, Kerr, Hughes, Berndt, Musgrove: "Human myeloid differentiation antigens identified by monoclonal antibodies: expression on leukemic cells." in: Pathology, Vol. 17, Issue 3, pp. 392-9, 1986 (PubMed).
Bradstock, Favaloro, Kabral, Kerr, Hughes, Musgrove: "Myeloid progenitor surface antigen identified by monoclonal antibody." in: British journal of haematology, Vol. 61, Issue 1, pp. 11-20, 1985 (PubMed).
|